Cue Biopharma is a clinical-stage biopharmaceutical company in Boston, Massachusetts developing a novel class of injectable biologics that selectively engage and modulate disease-specific T cells directly within the patient's body. Its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform is designed to harness the immune system without the adverse effects of broad systemic immune modulation. The company has refocused its portfolio on allergic and autoimmune disease, led by CUE-221, an anti-IgE antibody with a dual mechanism of action in Phase 2, and CUE-401, a bifunctional IL-2 and TGF-beta program advancing toward Phase 1. Earlier immuno-oncology programs including CUE-101 and CUE-102 came out of the same platform, and the company has partnered with Boehringer Ingelheim on autoimmune disease.